• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Osimertinib associated with longer overall survival versus comparator EGFR-TKIs

byThomas SuandDeepti Shroff Karhade
December 24, 2019
in Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles.

2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was substantial overlap between confidence intervals.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in managing sensitized non-small cell lung cancer. The third-generation irreversible EGFR-TKI osimertinib inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations and potentially penetrates the blood-brain barrier to directly interact with the central nervous system (CNS). The phase 3 FLAURA trial showed significantly longer progression-free survival in the osimertinib group than in the EGFR-TKI comparator group, but overall survival data were immature at the time of the primary analysis. In this final analysis, median overall survival was also found to be substantially higher in the osimertinib group. No new safety signals were detected, with grade 3 or higher adverse events and treatment discontinuation occurring at similar rates in both groups. Strengths of this study included a double-blind design, a representative trial population, and confirmation of mutation status. One limitation was that the newer EGFR-TKI afatinib was not included in the comparator group, somewhat limiting the clinical significance of the study’s results.

Click here to read the study in NEJM

Relevant Reading: Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

In-Depth [randomized controlled trial]: In the double-blind, multicenter, phase 3 FLAURA trial, 556 patients with previously untreated, EGFR mutation-positive advanced NSCLC were stratified by mutation status (Ex19del or L858R) and race (Asian or Non-Asian) before being assigned in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg daily) or an earlier-generation EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). In the comparator group, 66% received gefitinib and 34% received erlotinib. The median progression-free survival was 18.9 months (95% confidence interval [CI], 15.2 to 21.4) in the osimertinib group and 10.2 months (95% CI, 9.6 to 11.1) in the standard EGFR-TKI group (hazard ratio for disease progression or death, 0.46; 95% CI, 0.37 to 0.57; P<0.001). At 18 months, progression-free survival among those with CNS metastases was 58% (95% CI, 40 to 72) in the osimertinib group and 40% (95% CI, 25 to 55) in the comparator group (HR for disease progression or death, 0.48; 95% CI, 0.26 to 0.86). The final analysis, conducted after 321 deaths had occurred (58% maturity), found that the median overall survival in the osimertinib group was 38.6 months (95% confidence interval [CI], 34.5 to 41.8) versus 31.8 months (95% CI, 26.6 to 36.0) in the comparator group (HR for death, 0.80; 95.05% CI, 0.64 to 1.00; P=0.046).

RELATED REPORTS

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: lung cancernon-small cell lung cancer (NSCLC)osimertinibtyrosine kinase inhibitor
Previous Post

2 Minute Medicine Rewind December 23, 2019

Next Post

Preoperative NT-proBNP concentration may help improve perioperative risk estimation

RelatedReports

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Next Post
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Preoperative NT-proBNP concentration may help improve perioperative risk estimation

#VisualAbstract: Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912)

#VisualAbstract: Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912)

Features predicting treatment failure in acute otitis media

Texting intervention reduces ER visits and improves vaccination rates among Latino families

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.